Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
PRAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.01 - $91.83
Previous CloseN/A
Volume51.58K
Average Volume (3M)390.40K
Market Cap
$1.48B
Enterprise Value$731.25M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 12, 2025EPS Estimate
-2.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.29
Shares Outstanding18,637,777
10 Day Avg. Volume429,539
30 Day Avg. Volume390,397
Standard Deviation0.33
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)942.70
Price to Cash Flow (P/CF)-13.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit298.83
Enterprise Value/Ebitda-4.47
Forecast
1Y Price Target
$177.86Price Target Upside138.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnding trial early due to overwhelming efficacy can lead to a strong positive move as investors will increase their view on the probability of success for the entire program.
Drug DevelopmentPraxis' CNS drug discovery engine is expected to produce more novel and differentiated clinical candidates in unmet and commercially promising areas.
Financial PositionThe company has a strong financial position with approximately $470 million in cash, providing runway into 2028, supporting its research and development activities.
Bears Say
Financial LossA net loss of $52M was reported for 3Q24, a notable increase in loss from $33M in 2Q24, largely due to higher operational expenses.
Trial DelaysPraxis Precision Medicines, Inc. delayed its recently planned interim analysis of Study 1 of the phase 3 essential tremor program to 1Q25 due to slower randomization.
Trial OutcomesEnding trial due to futility could lead to a significant negative impact on the stock due to recent study failures and difficulty in predicting CNS studies.
---
Ownership Overview
10.85% Insiders
19.33% Mutual Funds
3.00% Other Institutional Investors
53.17% Public Companies and Individual Investors
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $33.01 and its highest was $91.83 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $1.48B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Mar 12, 2025 which is in 18 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Nov 06, 2024. The company reported -$2.75 earnings per share for the quarter, missing the consensus estimate of -$1.989 by -$0.761.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -2.85.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 18,637,777 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$2.75 in its last earnings report, missing expectations of -$1.989. Following the earnings report the stock price went down -1.182%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
---
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$177.86 (138.77% Upside)
$177.86 (138.77% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 175.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.86%
12-Months-Change
Fundamentals
Return on Equity
-64.34%
Trailing 12-Months
Asset Growth
290.03%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.
---
PRAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Praxis's pipeline, particularly with promising results in their epilepsy programs and a solid financial position. However, there were concerns about delays in clinical trial timelines and challenges in managing placebo effects, which could impact future outcomes.Read More>---
PRAX Stock 12 Month Forecast
Average Price Target
$177.86
▲(138.77% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Cytokinetics
―
SAGE Therapeutics
―
Viking Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+80.10%
reiterated a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +80.10% per trade.
---